SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Abbasciano V, Tassinari D, Sartori S, Trevisani L, Arcudi D, Bianchi MP, Liboni A. 1995. Usefulness of coagulation markers in staging of gastric cancer. Cancer Detect Prev 19:331336.
  • Bick RL. 1978. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 5:126.
  • Carl-McGrath S, Lendeckel U, Ebert M, Wolter AB, Roessner A, Rocken C. 2004. The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer. Int J Oncol 25:12231232.
  • Kang X, Xu Y, Wu X, Liang Y, Wang C, Guo J, Wang Y, Chen M, Wu D, Wang Y, Bi S, Qiu Y, Lu P, Cheng J, Xiao B, Hu L, Gao X, Liu J, Wang Y, Song Y, Zhang L, Suo F, Chen T, Huang Z, Zhao Y, Lu H, Pan C, Tang H. 2005. Establish of the proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome (SARS). Clin Chem 51:5664.
  • Li SP, Xu X, Liu JD, Gao SX, Li N, Xu Y. 2006. Fibrinopeptide A with alanine truncation at N-terminal as a novel prognostic biomarker for gastric adenocarcinoma with lymph node involvement. In: Proceedings of American Association for Cancer Research. LB257 (Abstract).
  • Li YZ, Hu CJ, Leng XM, Zhao GF, Li N, Xu Y. 2009. Promising diagnostic biomarkers for primary biliary cirrhosis identified with magnetic beads and MALDI-TOF-MS. Anat Rec 292:455460.
  • Liang Y, Fang MR, Li JC, Liu CB, Rudd JA, Kung HF, Yew DTW. 2006. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol 81:176180.
  • Liu CB, Shen JM, Pan CQ, Yang LJ, Mou SH, Wang HB, Liang Y. 2010. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol 134:235241.
  • Murray CJ, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349:14981504.
  • Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572577.
  • Pisani P, Parkin DM, Bray F, Ferlay J. 1999. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:1829.
  • Poon TCW, Sung JJY, Chow SM, Ng EKW, Yu ACW, Chu ESH, Hui AMY, Leung WK. 2006. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 130:18581864.
  • Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:19371947.
  • Su Y, Shen J, Qian H, Ma H, Ji J, Ma H, Ma L, Zhang W, Meng L, Li Z, Wu J, Jin G, Zhang J, Shou C. 2007. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 98:3743.
  • van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:19992009.
  • Villanueva J, Lawlor K, Toledo-Crow R, Tempst P. 2006a. Automated serum peptide profiling. Nat Protoc 1:880891.
  • Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P. 2004. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76:15601570.
  • Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. 2006b. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271284.
  • Wang L, Su D, Yan HJ, Xu JH, Zheng ZG, Hu YJ, Pan XD, Ding XW, Chen C, Chen B, Mao WM, Meng XL. 2011. Primary study of lymph node metastasis-related serum biomarkers in breast cancer. Anat Rec 294:18181824.
  • Wang QT, Li YZ, Liang YF, Hu CJ, Zhai YH, Zhao GF, Zhang J, Li N, Ni AP, Chen WM, Xu Y. 2009. Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software. Anat Rec 292:604610.
  • Xu Y, Wellner D, Scheinberg DA. 1995. Substance P and bradykinin are natural inhibitors of CD13/aminopeptidase N. Biochem Biophys Res Commun 208:664674.
  • Xu Y, Wellner D, Scheinberg DA. 1997. Cryptic and regulatory epitopes in CD13/aminopeptidase N. Exp Hematol 25:521529.
  • Zeng Q, Sun XN, Ma LH, Chen L, Wang Y, Chen C, Ye ZY, Wu ZH, Li YZ, Xu Y. 2010. Biomarkers for the prediction of major adverse cardiovascular events in patients with acute coronary syndrome. Anat Rec 293:15121518.